MK-608

Source: Wikipedia, the free encyclopedia.
MK-608
Clinical data
Other names7-Deaza-2’-C-methyladenosine; 7DMA
Legal status
Legal status
Identifiers
  • (2R,3R,4R,5R)-2-(4-Aminopyrrolo[2,3-d]pyrimidin-7-yl)-5-(hydroxymethyl)-3-methyloxolane-3,4-diol
JSmol)
  • C[C@]1([C@@H]([C@H](O[C@H]1n2ccc3c2ncnc3N)CO)O)O
  • InChI=1S/C12H16N4O4/c1-12(19)8(18)7(4-17)20-11(12)16-3-2-6-9(13)14-5-15-10(6)16/h2-3,5,7-8,11,17-19H,4H2,1H3,(H2,13,14,15)/t7-,8-,11-,12-/m1/s1
  • Key:IRZRJANZDIOOIF-GAJNKVMBSA-N

MK-608 (7-deaza-2’-C-methyladenosine, 7DMA) is an

nucleoside analog). It was originally developed by Merck & Co. as a treatment for hepatitis C, but despite promising results in animal studies,[1][2] it was ultimately unsuccessful in clinical trials.[3] Subsequently it has been widely used in antiviral research and has shown activity against a range of viruses, including Dengue fever,[4] tick-borne encephalitis virus,[5] poliovirus,[6][7] and most recently Zika virus,[8][9] in both in vitro and animal models. Since it has already failed in human clinical trials previously, it is unlikely MK-608 itself will be developed as an antiviral medication, but the continuing lack of treatment options for these emerging viral diseases means that much research continues using MK-608 and related antiviral drugs.[10]

See also

References

This page is based on the copyrighted Wikipedia article: MK-608. Articles is available under the CC BY-SA 3.0 license; additional terms may apply.Privacy Policy